tiprankstipranks
Trending News
More News >

SSY Group Limited Reports 2024 Annual Results Amid Challenging Market Conditions

Story Highlights
  • SSY Group Limited operates in the pharmaceutical industry, focusing on intravenous infusion solutions and bulk pharmaceuticals.
  • In 2024, SSY Group’s revenue decreased by 10.7%, but the total dividend increased by 2.9%.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
SSY Group Limited Reports 2024 Annual Results Amid Challenging Market Conditions

Confident Investing Starts Here:

An announcement from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited faced a challenging business environment in 2024, marked by sluggish economic recovery and intensified trade protectionism. Despite these challenges, the company maintained stable development by focusing on innovation and optimizing its product mix. The company reported a revenue of approximately HK$5,773 million, a decrease of 10.7% from the previous year, and a net profit of HK$1,061 million, down by 19.5%. The company declared a final dividend of HK$0.095 per share, with a total dividend for the year increasing by 2.9%.

More about SSY Group

SSY Group Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on the production and sale of pharmaceutical products, including intravenous infusion solutions, bulk pharmaceuticals, and medical materials.

YTD Price Performance: -1.40%

Technical Sentiment Signal: Buy

Current Market Cap: $1.27B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1